On March 7, 2019 LIDDS AB reported that a collaboration agreement with Belina was signed in 2017 with the aim of using LIDDS depot technology in combination with a drug intended for the treatment of breast cancer (Press release, Lidds, MAR 7, 2019, View Source [SID1234555909]). The collaboration has now concluded.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

LIDDS has delivered the drug formulations with release profiles in line with Belina’s requests. Due to increased requirements for the drug’s dosing level, Belina has chosen not to continue with the collaboration.

-We have fulfilled our obligations and LIDDS has had full cost coverage for the collaboration. The collaboration has concluded as the dosing levels required have be adjusted and increased during the project, says Monica Wallter, CEO LIDDS.